ArticleAdvances in hematology2012
Secondary primary malignancies in multiple myeloma: an old NEMESIS revisited.
Article in Advances in hematology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 45 citations in OpenAlex.
- Allogeneic hematopoietic cell transplantation for therapy-related hematological malignancies in patients with multiple myeloma.Frontiers in oncology · 2026Article
- Second Primary Tumors After Primary Brain Tumors and Vice Versa: A Single-Center, Retrospective Study.Brain tumor research and treatment · 2025Article
- The risk and survival of multiple myeloma as the second primary malignancy in a single Chinese center.Translational cancer research · 2024Article
- Prognostic analysis of lung squamous cell carcinoma patients with second primary malignancies: a SEER database study.Frontiers in oncology · 2024Article
- Article
- Recent Advances in the Treatment and Supportive Care of POEMS Syndrome.Journal of clinical medicine · 2022Review
- Synthesis and In Vitro Activity of Novel Melphalan Analogs in Hematological Malignancy Cells.International journal of molecular sciences · 2022Article
- Co-occurrence of myeloid neoplasm and plasma cell neoplasm.Autopsy & case reports · 2022Article
- Lenalidomide induced secondary Acute Lymphoblastic Leukemia in a Multiple Myeloma patient: A case-report.Leukemia research reports · 2022Article
- Second primary malignancies in multiple myeloma: A review.Blood reviews · 2021Review
- First reported case of secondary mixed phenotype acute leukemia after multiple myeloma.American journal of blood research · 2021Article
- Second primary malignancies among cancer patients.Annals of translational medicine · 2020Article
- Article
- Article
- Glioblastoma Multiforme in a Patient with Multiple Myeloma: A Case Report and Literature Review.The Permanente journal · 2018Article
- The impact of prior malignancies on second malignancies and survival in MM patients: a population-based study.Blood advances · 2017Article
- Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed/refractory multiple myeloma patients.Cancer medicine · 2017Article
- A Case of Multiple Myeloma Following Bladder Cancer.International journal of hematology-oncology and stem cell research · 2016Article
- Second Primary Malignancies in Adults with Gastric Cancer - A US Population-Based Study.Frontiers in oncology · 2016Article
- Everything points to myeloma.Journal of general internal medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The treatment of myeloma has undergone extraordinary improvements in the past half century. These advances have been accompanied by a concern for secondary primary malignancies (SPMs). It has been known for decades that extended therapy with alkylating chemotherapy agents, such as melphalan, carries an increased risk of therapy-related myelodysplastic syndrome and/or acute myeloid leukemia (t-MDS/AML), with a cumulative risk as high as 10-15%. High-dose chemotherapy with autologous stem cell support became widely accepted for myeloma in the 1990s. Despite the use of high doses of melphalan, the risk of t-MDS/AML with this procedure is estimated to be less than 5%, with much of this risk attributable to pretransplant therapy. Recently, lenalidomide has come under scrutiny for its possible association with SPMs. It is too soon to declare a causal relationship at this time, but there appears to be an increased number of SPMs in reports from several studies using lenalidomide maintenance. Current studies should be amended and future studies planned to better define the risk of SPMs and the risk factors and mechanisms for its development. Patients should be educated regarding this potential concern but the current use of lenalidomide should not generally be altered until further data are available.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.